Acrobiosystems Co.Ltd.

301080 · SHE · Healthcare / Biotechnology

83.62CNY-11.08 (-11.70%)

Price History

Full chart

Market Stats

Previous Close94.70

Open88.80

Day Range81.42 – 91.72

52-Week Range35.30 – 141.07

Volume18.65M

Market Cap23.65B

P/E (TTM)131.84

Forward P/E0.00

EPS1.07

Dividend Yield0.43%

Beta0.72

50-Day Avg83.94

200-Day Avg56.98

About

Acrobiosystems Co.,Ltd. engages in the development and manufacture of recombinant proteins, antibodies, and other biological reagents for pharmaceutical and biotechnology companies, and research institutions. It provides kits, scientific services, and other related products under the Resilient Supply, CytoPak, SAFENSURE, FLAG, Star Staining, Aneuro, ComboX, and GENPower brands. The company also offers cell therapies, gene therapies, therapeutic antibodies, antibody-drug conjugates, core reagents for infectious disease research, and solutions for metabolic and autoimmune disease drug development. In addition, it provides custom reagent, assay development, and analytical services. Further, the company is involved in general business, sales and technical services of biological products, manufacture and sells medical devices, research and development of biological reagent products, business information consulting and conference, and company testing service businesses. The company's products are used in drug screening and optimization for diseases such as cancer, autoimmune diseases, cardiovascular diseases, and infectious diseases; diagnostic reagent development and optimization; preclinical and clinical trials; and drug manufacturing processes and process control. Acrobiosystems Co.,Ltd. was founded in 2010 and is based in Beijing, China.

Company Details

SectorHealthcare
IndustryBiotechnology
CEOMr. Yiding Chen
Employees926
HeadquartersBuilding 4, Building 5, Beijing, China, 100176, China
Websitehttps://www.acrobiosystems.cn

Leadership

Mr. Yiding ChenGM & Chairman of the Board · b. 1977
Mr. Tao LinDeputy GM, CFO, Chief Accountant & Secretary of the Board of Directors · b. 1989
Mr. Jingyun MiaoDeputy GM & Director · b. 1978
Ms. Xu HuangDeputy General Manager · b. 1977
Ms. Xiamin ChenDeputy General Manager · b. 1976

Financials

Income Statement

Currency: CNY	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Revenue	103.29M	246.32M	384.99M	474.43M	543.65M	645.02M	838.12M
Growth (%)	-	+138.47%	+56.30%	+23.23%	+14.59%	+18.65%	+29.94%
Cost of Revenue	11.92M	19.94M	28.62M	35.55M	47.49M	58.49M	74.13M
Gross Profit	91.38M	226.38M	356.37M	438.88M	496.16M	586.54M	763.99M
Gross Margin	88.46%	91.91%	92.57%	92.51%	91.26%	90.93%	91.16%
Operating Expense	76.13M	86.41M	164.36M	273.26M	363.75M	477.22M	567.03M
Operating Income	15.24M	139.97M	192.01M	165.63M	132.42M	109.32M	196.96M
Operating Margin	14.76%	56.83%	49.87%	34.91%	24.36%	16.95%	23.50%
EBITDA	19.92M	145.61M	213.93M	252.43M	205.39M	181.71M	240.15M
EBITDA Margin	19.29%	59.12%	55.57%	53.21%	37.78%	28.17%	28.65%
Net Income	11.10M	115.88M	174.21M	203.73M	153.59M	123.83M	165.57M
Net Income Margin	10.75%	47.05%	45.25%	42.94%	28.25%	19.20%	19.75%
R&D	21.31M	30.65M	59.55M	113.85M	124.92M	165.35M	184.17M
R&D as % of Total Revenue	20.63%	12.44%	15.47%	24.00%	22.98%	25.63%	21.97%
Interest Expense	-	-	1.15M	2.95M	2.70M	3.54M	2.69M
Interest Expense % of Total Revenue	-	-	0.30%	0.62%	0.50%	0.55%	0.32%

Balance Sheet

Currency: CNY	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Assets	113.46M	241.34M	2.54B	2.74B	2.81B	2.91B	3.01B
Total Liabilities	16.12M	41.28M	78.84M	167.25M	225.22M	303.89M	351.90M
Total Equity	97.39M	200.30M	2.47B	2.56B	2.59B	2.62B	2.66B
Cash	43.94M	100.33M	2.01B	1.83B	1.98B	1.89B	946.83M

Cash Flow

Currency: CNY	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Operating Cash Flow	20.40M	96.50M	138.01M	202.19M	111.20M	84.71M	355.74M
Capital Expenditure	10.09M	14.98M	61.66M	284.29M	128.69M	167.26M	205.08M
Free Cash Flow	10.31M	81.52M	76.35M	-82.10M	-17.49M	-82.56M	150.66M
Dividends Paid	-	20.00M	-	120.00M	120.00M	108.21M	85.55M
FCF to OCF	50.53%	84.48%	55.32%	-40.61%	-15.73%	-97.46%	42.35%
Dividend Paid to FCF	-	24.53%	-	-146.16%	-686.10%	-131.08%	56.78%

Earnings

Report Date	Dec 31, 2021	Apr 22, 2022	Aug 29, 2022	Oct 25, 2022	Apr 25, 2023	Aug 28, 2023	Oct 29, 2023	Apr 23, 2024	Aug 30, 2024	Oct 29, 2024	Apr 20, 2025	Aug 22, 2025	Oct 28, 2025	Dec 31, 2025	Apr 20, 2026	Aug 28, 2026
EPS Estimate	-	-	-	-	-	-	-	-	-	-	0.24	0.23	0.35	0.31	0.45	0.36
EPS Actual	0.32	0.67	0.69	0.71	0.47	0.38	0.30	0.21	0.16	0.22	0.34	0.26	0.29	0.20	0.28	0.31
Surprise	-	-	-	-	-	-	-	-	-	-	40.33%	12.17%	-17.14%	-35.81%	-37.78%	-13.89%
Timing	-	Pre-market	Pre-market	After-hours	Pre-market	Pre-market	After-hours	Pre-market	-	Pre-market	Pre-market	-	Pre-market	-	Pre-market	After-hours

Key Statistics & Ratios

Market Cap23.65B

Enterprise Value20.78B

Trailing P/E131.84

Forward P/E0.00

Price / Sales24.89

Price / Book8.19

EPS1.07

Book Value15.90

Revenue (TTM)950.35M

Gross Profit (TTM)789.43M

EBITDA194.93M

Profit Margin18.95%

Operating Margin12.99%

Return on Equity6.83%

Return on Assets3.17%

Shares Outstanding167.68M

Shares Float91.12M

Beta0.72

Dividend Yield0.43%

Dividend Rate0.60

Payout Ratio55.61%

Dividends

20261×

0.60Jun 11, 2026

20252×

0.29Jul 11, 20250.21Jan 24, 2025

20241×

0.64Jul 5, 2024

20231×

1.07Jun 7, 2023

20221×

0.71May 30, 2022

Stock Splits

Jul 11, 20251.4:1
Jun 7, 20231.5:1